DISEASE ACTIVITY SCORING: COMPARING PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS STARTING A FIRST BIOLOGIC AGENT

B. Harauqi1, L. Bessette2, D. Choquette3, F. Massicotte1, J.-P. Pelletier1, J.-P. Raynauld1, M.-A. Rémiillard1, D. Sauvageau1, E. Villeneuve1, and L. Couplaud1
1Institut de Rhumatologie de Montréal (IRM), 2Centre d’ostéopérose et de rhumatologie de Québec (CORQ)

INTRODUCTION

Visual analogue scales (VAS) are routinely used in daily clinical practice and are part of the different composite outcome measures such as the DAS, CDAI and SDAI. Studies often report weak to moderate positive correlations between physician and patient global assessment of disease activity. It is thought that they are driven by different considerations such acute phase reactant status for patients and more objective measures such as the swollen joint count and acute phase reactants for physicians. We hypothesized that while absolute values of patient and physician global disease activity do not always correlate, changes in these measures may offer a better correlation. To this end, we looked at global evaluation changes before and after introduction of a first biologic agent in patient with RA.

OBJECTIVES

We hypothesized that while absolute values of patient and physician global disease activity do not always correlate, changes in these measures may offer a better correlation. To this end, we looked at global evaluation changes before and after introduction of a first biologic agent in patient with RA.

METHODS

We included patients treated for at least 6 months with a first anti-TNF agent (adalimumab, etanercept or infliximab) starting in January 2005. The patient and physician global assessments of disease activity of RA patients were extracted from the RHUMADATA® clinical database and registry. Pearson correlations coefficients between pre-, post and pre-post changes in patient and physician assessments were computed (SAS v 9.13) and compared.

BASELINE CHARACTERISTICS

<table>
<thead>
<tr>
<th>N</th>
<th>Mean age (years)</th>
<th>Disease duration(years)</th>
<th>% Women</th>
<th>HAQ score</th>
<th>Morning stiffness (min)</th>
<th>Fatigue (VAS)</th>
<th>Pain (VAS)</th>
<th>CRP (mg/L)</th>
<th>ESR (mm/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>57.7 (12.9)</td>
<td>3.8 (1.6)</td>
<td>80.3%</td>
<td>1.2 (0.6)</td>
<td>90.9 (229.5)</td>
<td>4.2 (3.4)</td>
<td>5.5 (2.9)</td>
<td>15.4 (27.5)</td>
<td>25.6 (18.8)</td>
</tr>
</tbody>
</table>

RESULTS

The global disease activity scores from 83 patient-physician pairs were available for this analysis. The pretreatment assessments were made within 0 and 176 days (mean 33 days) of biologic initiation while the post treatment assessments occurred between 182 and 799 days (mean 268 days). The patient and physician pre, post, and pre-minus-post global assessment means and standard deviations are presented below. The correlation coefficients between patient and physician global activity assessment was 0.15 (p=0.19). Disease duration, gender, age and DAS28 scores did not influence the change in DAS. Similar results were observed in the PG changes except for disease duration where patients with < 2 years had smaller changes. The GLM revealed that no factors other than rater (physician or patient) explained the observed differences.

<table>
<thead>
<tr>
<th>Physician and patient global disease activity assessment</th>
<th>Mean</th>
<th>Std Dev</th>
<th>Mean</th>
<th>Std Dev</th>
<th>Mean</th>
<th>Std Dev</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-treatment</td>
<td>5.27</td>
<td>1.98</td>
<td>5.58</td>
<td>2.96</td>
<td>0.31</td>
<td>2.94</td>
</tr>
<tr>
<td>Post-treatment</td>
<td>1.42</td>
<td>1.79</td>
<td>3.79</td>
<td>2.81</td>
<td>2.37</td>
<td>3.02</td>
</tr>
<tr>
<td>Change</td>
<td>-3.85</td>
<td>2.31</td>
<td>-1.79</td>
<td>2.95</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

CONCLUSIONS

While the pretreatment global disease activity assessments showed moderate correlation, the change in these assessments exhibited a weak relationship. Both physicians and patients agree on disease activity improvement although their magnitudes differ. Of the factors explored, only rater (physician or patient) seem to explain these differences.

Supported by unrestricted grants from: Abdi/Ase, Amgen, BMS, Janssen, Pfizer, Roche and UCB Canada.

CONTACT

D. Choquette MD
Institut de Rhumatologie de Montreal
1151, Donna Street East
Montreal, Canada
dani.choquette.im@videotron.ca